On the Moscow Exchange derivatives market, trading has begun in deliverable futures and cash-settled incentive options on ordinary shares of the Human Stem Cell Institute (HSCI, MOEX: ISKJ).
Series of futures with execution in June and September 2023, two weekly and two monthly series of options are eligible for trading.
According to the press release of the Moscow Exchange: “Futures and stock options will expand the investment strategies of private and institutional investors.”
According to HSCI’s Investment Director Dmitry Krasotkin: “The introduction of futures and options on HSCI shares will allow investors to diversify their portfolios and gain additional risk hedging opportunities. They will be able to use these financial instruments to protect their positions from possible losses in the market or for extra profit.”
The Human Stem Cell Institute is a biotechnological holding with a portfolio of innovative platform developments, medical devices and services that implements them in healthcare. HSCI includes companies at different development stages: from seed to early growth and maturity.
HSCI creates high-tech products for high-margin markets with high revenue potential and a low competition. HSCI is focused on long-term growth in the value of its assets due to the growth of the healthcare market as a whole.